Gabapentin vs placebo
Participant‐reported pain relief of 50% or greater · adults with postherpetic neuralgia
1 finding from 1 review
- no estimate extracted7 studies · 2031 participantsModerate
Findings
What do systematic reviews say?
603 questions · 627 findings · 69 reviews · Pain, Palliative and Supportive Care
No studies found 111 · 17.7%GRADE not reported 27 · 4.3%Very low 191 · 30.5%Low 138 · 22%Moderate 100 · 15.9%High 60 · 9.6%
Gabapentin vs placebo
Withdrawals due to adverse events · adults with neuropathic pain
1 finding from 1 review
- no estimate extracted22 studies · 4346 participantsHigh
Gabapentin vs placebo
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
- no estimate extracted19 studies · 3948 participantsModerate
Gabapentin vs placebo
Death · adults with neuropathic pain
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Gabapentin vs placebo
IMMPACT definition ‐ any substantial pain benefit · adults with postherpetic neuralgia
1 finding from 1 review
- no estimate extracted8 studies · 2260 participantsModerate
Gabapentin vs placebo
Patient Global Impression of Change much or very much improved · adults with postherpetic neuralgia
1 finding from 1 review
- no estimate extracted7 studies · 2013 participantsModerate
Gabapentin vs placebo
IMMPACT definition ‐ any at least moderate pain benefit · adults with postherpetic neuralgia
1 finding from 1 review
- no estimate extracted8 studies · 2260 participantsModerate
Gabapentin vs placebo
Participant‐reported pain relief of 50% or greater · people with diabetic peripheral neuropathy
1 finding from 1 review
- no estimate extracted6 studies · 1331 participantsModerate
Gabapentin vs placebo
'Substantial benefit' (≥ 50% reduction in pain or PGIC very much improved) · people with diabetic peripheral neuropathy
1 finding from 1 review
- no estimate extracted6 studies · 1331 participantsModerate
Gabapentin vs placebo
Patient Global Impression of Change much or very much improved · people with diabetic peripheral neuropathy
1 finding from 1 review
- no estimate extracted5 studies · 695 participantsModerate
Gabapentin vs placebo
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · people with diabetic peripheral neuropathy
1 finding from 1 review
- no estimate extracted7 studies · 1439 participantsModerate
Gabapentin vs placebo
Proportion of participants experiencing adverse events · adults with neuropathic pain
1 finding from 1 review
- no estimate extracted18 studies · 4279 participantsModerate
Summary of findings: liposomal bupivacaine vs placebo
Cumulative pain score from the end of operation (0 hours) to 72 hours (NRS 0 to 10) · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
- Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 189 participantsVery low
Summary of findings: liposomal bupivacaine vs placebo
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
- Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 382 participantsLow
Summary of findings: liposomal bupivacaine vs placebo
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · aged 18 years and older undergoing elective surgery at any surgical site
The review found no eligible studies for this question.
1 finding from 1 review
- Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings: liposomal bupivacaine vs placebo
Time to first postoperative opioid dose over initial 72 hours · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
- Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 382 participantsLow
Summary of findings: liposomal bupivacaine vs placebo
Total postoperative opioid consumption over first 72 hours · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
- Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 189 participantsVery low
Summary of findings: liposomal bupivacaine vs placebo
Percentage of participants not requiring postoperative opioids over initial 72 hours · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
- Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 382 participantsVery low
Summary of findings: liposomal bupivacaine vs placebo
Incidence of adverse events within 30 days of surgery · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
- Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 382 participantsLow
Morphine vs placebo
Reported outcomes approximating to 30% reduction in pain · adults with neuropathic pain
1 finding from 1 review
- no estimate extracted62 participantsVery low